Smith & Nephew/£SN
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Ticker
£SN
Sector
Primary listing
LSE
Employees
17,000
Headquarters
Website
Smith & Nephew Metrics
BasicAdvanced
£11B
30.03
£0.42
0.67
£0.29
2.26%
Price and volume
Market cap
£11B
Beta
0.67
52-week high
£14.42
52-week low
£9.15
Average daily volume
3.3M
Dividend rate
£0.29
Financial strength
Current ratio
3.003
Quick ratio
1.402
Long term debt to equity
59.556
Total debt to equity
62.392
Dividend payout ratio (TTM)
66.60%
Interest coverage (TTM)
6.85%
Profitability
EBITDA (TTM)
1,090.958
Gross margin (TTM)
70.59%
Net profit margin (TTM)
8.26%
Operating margin (TTM)
16.60%
Effective tax rate (TTM)
19.11%
Revenue per employee (TTM)
£265,900
Management effectiveness
Return on assets (TTM)
5.81%
Return on equity (TTM)
9.14%
Valuation
Price to earnings (TTM)
30.033
Price to revenue (TTM)
2.464
Price to book
2
Price to tangible book (TTM)
7.57
Price to free cash flow (TTM)
18.373
Free cash flow yield (TTM)
5.44%
Free cash flow per share (TTM)
0.693
Dividend yield (TTM)
2.26%
Growth
Revenue change (TTM)
5.35%
Earnings per share change (TTM)
59.91%
3-year revenue growth (CAGR)
4.47%
10-year revenue growth (CAGR)
2.44%
3-year earnings per share growth (CAGR)
-0.44%
10-year earnings per share growth (CAGR)
-1.03%
3-year dividend per share growth (CAGR)
0.53%
10-year dividend per share growth (CAGR)
2.28%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Bulls say / Bears say
First half 2025 revenue rose 4.7% on a reported basis (5.0% underlying) and operating profit jumped 30.6% to $429 million, illustrating strong top- and bottom-line momentum (Smith & Nephew Q2/H1 Results)
A $500 million share buyback programme was launched for H2 2025, underlining robust cash flow generation and a healthy balance sheet to support shareholder returns (Smith & Nephew Buyback RNS)
The US market delivered 8.7% underlying revenue growth in Q2 2025, demonstrating resilience and leadership in the firm’s largest geography (Smith & Nephew Q2/H1 Results)
China’s extension of the volume-based procurement (VBP) programme is expected to create a $25 million revenue headwind in Sports Medicine and a $15–20 million impact from tariffs in H2 2025, pressuring growth outside the US (Smith & Nephew Q2/H1 Results)
Proposed updates to US Medicare reimbursement for skin substitutes, shifting to a single payment, are anticipated to weigh on Advanced Wound Bioactives sales and profitability in 2026 (Smith & Nephew Q2/H1 Results)
Emerging Markets saw a 0.2% underlying revenue decline in Q2 2025, reflecting ongoing vulnerability to regional destocking and demand volatility (Smith & Nephew Q2/H1 Results)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2025.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Smith & Nephew stock?
Smith & Nephew (SN) has a market cap of £11B as of November 09, 2025.
What is the P/E ratio for Smith & Nephew stock?
The price to earnings (P/E) ratio for Smith & Nephew (SN) stock is 30.03 as of November 09, 2025.
Does Smith & Nephew stock pay dividends?
Yes, the Smith & Nephew (SN) stock pays dividends to shareholders. As of November 09, 2025, the dividend rate is £0.2874 and the yield is 2.26%. Smith & Nephew has a payout ratio of 66.6% on a trailing twelve-month basis.
When is the next Smith & Nephew dividend payment date?
The next Smith & Nephew (SN) dividend payment date is unconfirmed.
What is the beta indicator for Smith & Nephew?
Smith & Nephew (SN) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.